David Dobies, MD
Interventional Cardiology · Grand Blanc, MINPI 1689642415
Payments from drug & device makers
Across 216 payments — averaging $78.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- AstraZeneca$3K
- Boston Scientific$2K
- American Regent$1K
- Boehringer Ingelheim$452
- Medtronic$345
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$2,00029%
- Food & beverage$4,88370%
- Education$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $7,030 |
| AstraZeneca | 17 | $3,170 |
| Boston Scientific | 2 | $1,530 |
| American Regent | 1 | $1,335 |
| Boehringer Ingelheim | 15 | $452 |
| Medtronic(2 entities) | 14 | $345 |
| Johnson & Johnson | 19 | $337 |
| Abiomed | 7 | $233 |
| Merck | 12 | $217 |
| Novo Nordisk | 5 | $216 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $191 |
| Edwards Lifesciences | 5 | $183 |
| Amgen | 9 | $169 |
| Pfizer | 11 | $149 |
| Cordis US CORP. | 1 | $149 |
| Astellas Pharma US Inc | 4 | $137 |
| Actelion Pharmaceuticals US, Inc. | 7 | $134 |
| Siemens Medical Solutions USA, Inc. | 1 | $130 |
| Biotronik Inc. | 1 | $129 |
| Baxter Healthcare | 3 | $77 |
| E.r. Squibb & Sons, L.L.C. | 5 | $72 |
| Philips North America LLC | 5 | $72 |
| Irhythm Technologies, Inc. | 4 | $71 |
| Shockwave Medical, Inc | 3 | $61 |
| Innovation Technologies Inc | 2 | $49 |
| Vifor Pharma, Inc. | 2 | $47 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Livanova USA, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Terumo Medical Corporation | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Sanofi | 1 | $21 |
| Chiesi USA, Inc. | 1 | $19 |
| Elutia, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Atricure, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Heartflow, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$2,000
- JARDIANCE$229
- MYNX CONTROL$149
- CorPath GRX$130
- PK Papyrus$129
- Orsiro Mission$129
- PRO-Kinetic Energy$129
- Passeo-18$129
- FARXIGA$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$109
- Telescope$102
How this compares
$17,015 in reported general payments places this provider in the 60th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 223 | $145,608 |
| JardianceEmpagliflozin | 168 | $126,895 |
| FarxigaDapagliflozin Propanediol | 131 | $88,916 |
| BrilintaTicagrelor | 55 | $27,586 |
| OzempicSemaglutide | 27 | $25,351 |
| XareltoRivaroxaban | 18 | $12,364 |
| Eplerenone | 188 | $8,699 |
| Ranolazine ErRanolazine | 59 | $4,567 |
| Valsartan | 329 | $3,751 |
| Colchicine | 79 | $3,747 |
| Potassium Chloride | 97 | $1,817 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 121 | $1,792 |
| Atorvastatin Calcium | 221 | $1,347 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 120 | $1,216 |
| Nitroglycerin | 85 | $955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $149 | $145,608223 claims |
| Boehringer IngelheimJardiance | $452 | $126,895168 claims |
| AstraZenecaFarxiga, Brilinta | $3,170 | $116,502186 claims |
| Novo NordiskOzempic | $216 | $25,35127 claims |
| Johnson & JohnsonXarelto | $337 | $12,36418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Grand Blanc
- Frank TilliGrand Blanc$85K
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.